Masayo Ogawa
AstraZeneca (Brazil)(BR)Alexion Pharmaceuticals (United States)(US)AstraZeneca (United States)(US)
Publications by Year
Research Areas
Complement system in diseases, Renal Diseases and Glomerulopathies, Adenosine and Purinergic Signaling, Blood groups and transfusion, Coagulation, Bradykinin, Polyphosphates, and Angioedema
Most-Cited Works
- → Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome(2013)1,539 cited
- → Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial(2016)301 cited
- → Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome(2016)290 cited
- → Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS(2015)195 cited
- → Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome(2018)169 cited
- → Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies(2019)89 cited